ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure

Go back to ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
(NASDAQ: CHFS) Delayed: 5.28 --0 (-0%)
Previous Close $5.28    52 Week High
Open $5.28    52 Week Low
Day High $5.28    P/E N/A 
Day Low $5.28    EPS
Volume 2,292,106       

(NASDAQ: NUWE) Delayed: 2.60 +0.09 (3.59%)
Previous Close $2.51    52 Week High
Open $2.50    52 Week Low
Day High $2.60    P/E N/A 
Day Low $2.41    EPS
Volume 676,225